Clinical Development of a Large Surface Area Microparticle Drug Platform to Treat Solid Tumors
DFB formed NanOlogy™ in 2015 to advance intratumoral drug therapies to increase the effectiveness of cancer treatment while minimizing systemic side effects.
NanOlogy, LLC is a company formed by DFB in collaboration with CritiTech, Inc. of Lawrence, KS to finance and develop a breakthrough particle engineering technology platform enabling locally delivered drug therapies aimed at improving the treatment of solid tumors without adding toxicity.